Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib and Lapatinib in Metastatic Triple Negative Breast Cancer
NCT02158507Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Sep 2014
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of veliparib in triple-negative breast cancer (TNBC), sponsored by University of Alabama at Birmingham. Primary endpoint: Number of Subjects Experiencing Study-related Toxicities at 4 years. Started Sep 2014; status: completed.
02
Drugs
veliparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02158507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02158507.